Trial Profile
Phase I trial of VIS 513 as a potential therapy for dengue fever.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs VIS 513 (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors Visterra
- 18 Oct 2017 According to Visterra media release, company plans to initiate the trial in 2018.
- 07 Oct 2014 New trial record